Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Revance Therapeutics, Inc. | rvnc1231201610kex321-certi.htm |
| EX-32.2 - EXHIBIT 32.2 - Revance Therapeutics, Inc. | rvnc1231201610kex322-certi.htm |
| EX-31.2 - EXHIBIT 31.2 - Revance Therapeutics, Inc. | rvnc1231201610kex312-certi.htm |
| EX-31.1 - EXHIBIT 31.1 - Revance Therapeutics, Inc. | rvnc1231201610kex311-certi.htm |
| EX-10.26 - EXHIBIT 10.26 - Revance Therapeutics, Inc. | rvnc1231201610kex1026-2017.htm |
| EX-10.25 - EXHIBIT 10.25 - Revance Therapeutics, Inc. | rvnc1231201610kex1025-amen.htm |
| EX-10.24 - EXHIBIT 10.24 - Revance Therapeutics, Inc. | rvnc1231201610kex1024-amen.htm |
| 10-K - 10-K - Revance Therapeutics, Inc. | rvnc1231201610k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Forms S‑8 (Nos. 333-209949, 333-208543, 333-203235, 333-198499, and 333-193963) and the Registration Statements on Form S-3 (Nos. 333-210001 and 333-207469) of Revance Therapeutics Inc. of our report dated February 28, 2017 relating to the financial statements, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
San Jose, California
San Jose, California
February 28, 2017